Development of a novel class of interleukin-2 immunotherapies for m...
... immunotherapies for metastatic cancer. Swiss Medical Weekly, 149:w14697. Copy Abstract Tumour immunotherapy, and ... Development of a novel class of interleukin-2 immunotherapies for metastatic cancer - Zurich Open ... Development of a novel class of interleukin-2 immunotherapies for metastatic cancer - Zurich Open ... Development of a novel class of interleukin-2 immunotherapies for metastatic cancer - Zurich Open ...
Emerging immunotargets and immunotherapies in prostate cancer - Zur...
... Emerging immunotargets and immunotherapies in prostate cancer - Zurich Open Repository and Archive ... Emerging immunotargets and immunotherapies in prostate cancer - Zurich Open Repository and Archive ... Emerging immunotargets and immunotherapies in prostate cancer - Zurich Open Repository and Archive ...
ImmunOs Therapeutics AG
... novel immunotherapies that enhance the efficacy of market leading checkpoint inhibitors and ... novel immunotherapies that enhance the efficacy of market leading checkpoint inhibitors and ...
Immunity, Hypoxia and Metabolism - the ménage à trois of cancer: im...
... restrictive TME and as important players in the anti-tumor immune response; iii) to define how immunotherapies ... and metabolites within the TME impinge on the success of immunotherapies. By analyzing preclinical and ... restrictive TME and as important players in the anti-tumor immune response; iii) to define how immunotherapies ... and metabolites within the TME impinge on the success of immunotherapies. By analyzing preclinical and ...
http://cdr-life.com/wp-content/uploads/2018/05/PR_20180523.pdf
... of novel immunotherapies in patient biopsies ZURICH, Switzerland, May 23, 2018 – CDR-Life inc. has ... technology. The collaboration will use synergies between the modular multispecific immunotherapies from CDR ... of novel immunotherapies in patient biopsies ZURICH, Switzerland, May 23, 2018 – CDR-Life inc. has ... technology. The collaboration will use synergies between the modular multispecific immunotherapies from CDR ...
https://www.virometix.com/wp-content/uploads/2022/03/Oncometix_Job-...
... , Switzerland, towards the evaluation of nanoparticle-based cancer vaccines and immunotherapies ... vaccine targets and immunotherapies • Mammalian cell culture and experience with cancer cell lines ... , Switzerland, towards the evaluation of nanoparticle-based cancer vaccines and immunotherapies ... vaccine targets and immunotherapies • Mammalian cell culture and experience with cancer cell lines ...
Jan Kisielow, PhD • Repertoire Immune Medicines
... provide the basis for personalized immunotherapies. He earned his PhD in cell biology from the Basel ... antigenic reactivity of T cells to provide the basis for personalized immunotherapies. He earned his PhD in ...
UZH - UZH Innovation Hub - UZH spin-off Anaveon successfully closed...
... . based in the a UK. Anaveon works on a new approach for developing immunotherapies for cancer. The ... approach for developing immunotherapies for cancer. The technology was developed by Prof. Onur Boyman. The ...
UZH - Institute for Regenerative Medicine • IREM - Antibody-based R...
... immunotherapies for neurodegenerative diseases, including Aducanumab resulting from research conducted at the ... Regeneration With the advent of clinically effective immunotherapies for neurodegenerative diseases, including ...
https://www.virometix.com/wp-content/uploads/2022/01/Oncometix_Job-...
... evaluation of nanoparticle-based cancer vaccines and immunotherapies as part of a bigger team of biologists ... tests and experiments for the functional validation of novel cancer vaccine targets and immunotherapies ... evaluation of nanoparticle-based cancer vaccines and immunotherapies as part of a bigger team of biologists ... tests and experiments for the functional validation of novel cancer vaccine targets and immunotherapies ...
